Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cytomegalovirus Retinitis: early-phase trial registry
A small indexed set (7 trials) with no open enrollment listed right now.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · none currently recruiting · #2,497 of 28,707 conditions by registered trial count
Cytomegalovirus Retinitis: 7 US clinical trials tracked, none currently recruiting.
Cytomegalovirus Retinitis is the subject of 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.
Enrollment posture brief
Registry condition cytomegalovirus-retinitis
OPEN 0 | RECR 0% | LATE 1 | EARLY 2 | RANK #2497 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Cytomegalovirus Retinitis has no open enrollment in this registry pull (7 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cytomegalovirus Retinitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cytomegalovirus Retinitis is recruiting below its size-band peers.
0 of 7 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cytomegalovirus Retinitis research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 7 trials (42.9%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Cytomegalovirus Retinitis enrolment sits around 156 participants.
Median target enrolment is 156 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Cytomegalovirus Retinitis research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000665
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
Hoffmann-La Roche
NCT00002222
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000691
Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000693
Efficacy of Elevated CD4 Counts on CMV Retinitis
National Eye Institute (NEI)
NCT00091884
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Hoffmann-La Roche
NCT00002377
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
Agouron Pharmaceuticals
NCT00002169
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cytomegalovirus Retinitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cytomegalovirus Retinitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cytomegalovirus Retinitis page
7 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Cytomegalovirus Retinitis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Cytomegalovirus Retinitis trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cytomegalovirus Retinitis condition card totals 7 registered trials; most-linked intervention Ganciclovir; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.